Long formoterol

Add standing treatment with one or more long-acting bron-chodilators (i.e., tiotropium, salmeterol, and formoterol)... 

Salmeterol and formoterol are long-acting inhaled p2-agonists that provide up to 12 hours of bronchodilation after a single dose. Both agents are approved for the chronic prevention of... 

Long-Acting p2 Agonists Formoterol Inhalation 1-3 minutes 1-3 hours 12 hours Powder (12 mcg/inhalation)... 

Several studies have shown an additive effect with the combination of inhaled corticosteroids and long-acting bronchodilators. Combination therapy with salmeterol plus fluticasone or formoterol plus budesonide is associated with greater improvements in FEVj, health status, and exacerbation frequency than either agent alone. The availability of combination inhalers makes administration of both drugs convenient and decreases the total number of inhalations needed daily. 

Jeppsson A-B, Nilsson E, Waldeck B (1994) Formoterol and salmeterol are both long acting compared to terbutaline in the isolated perfused and ventilated guinea-pig lung. Eur J Pharmacol 257 137-143. 

Orciprenaline is a partially selective adrenoceptor-agonist and hence it is more likely to have effects on the cardiovascular system, such as arrhythmias, than the selective adrenoceptor-agonists, such as salbutamol, terbutaline and the long-acting beta-agonists salmeterol and formoterol. Orciprenaline is available only as tablets or syrup and can be prescribed to 4-year-old children. 

Patients receiving fluticasone propionate/salmeterol twice daily should not use salmeterol or other inhaled, long-acting 2-agonists (eg, formoterol) for... 

Budesonide/Formoterol (Symbicort) [Anti-inflammatory> Bronchodilator/Beta-2-Agonist] WARNING Long-acting... 

A fixed combination of ICS plus long-acting P2-agonist, such as fluticasone/salmeterol or budes-onide/formoterol, is available and may simplify therapy. However, new insights in treating patients with these combinations on an as needed regimen in combination with a daily low dose maintenance therapy, is still debated. 

Formoterol is a long-acting selective beta2-adrenoceptor agonist that is more potent than salmeterol (1) and has a similar duration of action (12 hours) but a rapid onset of effect similar to that of salbutamol. It is available as a multidose, pressurized aerosol and as a dry powder inhaler, delivering 0.006 or 0.012 mg per dose. The usual dose is 0.012 mg bd. 

---